Education
About Us
Working with TipRanks
Follow Us
Newron Pharmaceuticals SpA (CH:NWRN)
:NWRN
NWRN Stock Chart & Stats
CHF27.85
-CHF0.12(-1.32%)
At close: 4:00 PM EST
CHF27.85
-CHF0.12(-1.32%)
Day’s Range― - ―
52-Week RangeCHF5.20 - CHF31.85
Previous CloseN/A
Volume17.86K
Average Volume (3M)170.30K
Market Cap
CHF608.44M
Enterprise ValueCHF141.69M
Total Cash (Recent Filing)CHF43.20M
Total Debt (Recent Filing)CHF52.57M
Price to Earnings (P/E)23.3
Beta2.01
Next Earnings
Mar 24, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding20,014,585
10 Day Avg. Volume255,106
30 Day Avg. Volume170,297
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)121.21
Price to Sales (P/S)3.44
P/FCF Ratio-10.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF43.00Price Target Upside54.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial And Strategic Upside From Successful Pivotal ResultsEvenamide's demonstrated efficacy and favorable safety profile in prior studies, together with ongoing global Phase 3 enrollment and expectations for top-line data to support U.S. submissions, could attract strategic acquirers and create significant upside if trials succeed.
Patent ProtectionEuropean Patent Office granting an additional composition-of-matter patent combined with national-phase filings in key countries strengthens evenamide's intellectual property position and delays potential generic competition, supporting long-term exclusivity.
Pivotal Trial Program And Regulatory ApprovalsRegulatory and ethics approvals in the U.S. and authorization to initiate the ENIGMA-TRS 2 Phase 3 study enable continuation of a global pivotal program designed to enroll a diverse patient population across multiple regions, enhancing the path toward broad labeling.
Bears Say
Geographic Concentration RiskHeavy reliance on successful commercialization in the U.S. and Europe concentrates the drug's value and increases downside if regulatory approvals or market uptake falter in those regions.
Revenue Diversification RiskLimited revenue diversification outside of core Western markets could leave overall commercial performance exposed if expansion in other regions does not offset setbacks in the U.S. or Europe.
Valuation Sensitivity To Key-market OutcomesCompany valuation is likely to be highly sensitive to trial readouts and regulatory decisions in the U.S. and Europe, creating potential for sharp stock swings around those milestones.
NWRN FAQ
What was Newron Pharmaceuticals SpA’s price range in the past 12 months?
Newron Pharmaceuticals SpA lowest stock price was CHF5.20 and its highest was CHF31.85 in the past 12 months.
What is Newron Pharmaceuticals SpA’s market cap?
Newron Pharmaceuticals SpA’s market cap is CHF608.44M.
When is Newron Pharmaceuticals SpA’s upcoming earnings report date?
Newron Pharmaceuticals SpA’s upcoming earnings report date is Mar 24, 2026 which is in 68 days.
How were Newron Pharmaceuticals SpA’s earnings last quarter?
Newron Pharmaceuticals SpA released its earnings results on Sep 16, 2025. The company reported CHF0 earnings per share for the quarter, beating the consensus estimate of -CHF0.38 by CHF0.38.
Is Newron Pharmaceuticals SpA overvalued?
According to Wall Street analysts Newron Pharmaceuticals SpA’s price is currently Undervalued.
Does Newron Pharmaceuticals SpA pay dividends?
Newron Pharmaceuticals SpA does not currently pay dividends.
What is Newron Pharmaceuticals SpA’s EPS estimate?
Newron Pharmaceuticals SpA’s EPS estimate is -0.07.
How many shares outstanding does Newron Pharmaceuticals SpA have?
Newron Pharmaceuticals SpA has 20,014,585 shares outstanding.
What happened to Newron Pharmaceuticals SpA’s price movement after its last earnings report?
Newron Pharmaceuticals SpA reported an EPS of CHF0 in its last earnings report, beating expectations of -CHF0.38. Following the earnings report the stock price went up 6.257%.
Which hedge fund is a major shareholder of Newron Pharmaceuticals SpA?
Currently, no hedge funds are holding shares in CH:NWRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Newron Pharmaceuticals SpA
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.
NWRN Stock 12 Month Forecast
Average Price Target
CHF43.00
▲(54.39% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Santhera Pharmaceuticals Holding
―
Xlife Sciences Ltd.
―
Options Prices
Currently, No data available
---